Plain-English translation of NCT05362760 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
The MINERVA Trial is testing abemaciclib — a newer type of cancer medication — combined with hormone therapy in women whose breast cancer has spread or come back. This study focuses not just on whether the medication works, but also on quality of life and side effects, which patients will track using a user-friendly app on their phone or computer.
This medication combination is already used in some patients, but doctors want to understand it better — specifically, how it affects daily life, how well it controls cancer long-term, and whether blood tests can predict who will benefit most from the treatment.
You likely qualify if…
You likely don't qualify if…
You will take abemaciclib as a pill twice daily, combined with one of two hormone therapy options (either a daily pill or injections), depending on which group you are assigned to. Throughout the trial, you will use a smartphone or web-based app to log side effects like diarrhea and how you're feeling every day. You'll have regular clinic visits with your doctor to check your health, and researchers may also take blood samples to study genetic markers that might explain why the treatment works for some patients but not others.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
Germany